Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558595 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT02558595: Completed Phase 2 study, sponsored by University of Kansas Medical Center.
NCT02558595 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558595, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.
Primary Outcome
Sirtuin 1 deacetylates p53 protein, and niacinamide inhibits sirtuin 1. So an increase in acetylated/total p53 ratio in PBMC will be used as a marker of biological efficacy.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Niacinamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-09-22 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 2 |
What the finished NCT02558595 record still lists
NCT02558595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02558595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02558595 about?
NCT02558595 is a clinical study titled "Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)". The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.
What is the current status of trial NCT02558595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2015-09-22. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT02558595?
The interventions under investigation include: Placebo (OTHER), Niacinamide (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02558595?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02558595's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI